SCHEMBL16399290

SCHEMBL16399290

CCOC(=O)c1cnc(/C=C/c2cccc(C(F)(F)F)c2)s1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.48
▸ MEN1 O00255 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ P4HB P07237 1/20 0.45
▸ NFE2L2 Q16236 1/20 0.44
▸ HTT P42858 2/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ HPGD P15428 1/20 0.44
▸ CHRNB2 P17787 1/20 0.43
▸ CHRNB4 P30926 1/20 0.43
▸ CHRNA3 P32297 1/20 0.43
▸ CHRNA7 P36544 1/20 0.43
▸ CHRNA4 P43681 1/20 0.43
▸ CDC7 O00311 1/20 0.42
▸ DBF4 Q9UBU7 1/20 0.42
▸ LMNA P02545 1/20 0.41
▸ TP53 P04637 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16399292 1.00 MAPT (0.48) MAPTMEN1KMT2AP4HBNFE2L2
SCHEMBL18002949 0.87 CDC7 (0.48) MAPTMEN1KMT2ACHRNB2CHRNB4
SCHEMBL16399538 0.79 MAPT (0.51) MAPTMEN1KMT2AP4HBNFE2L2
SCHEMBL16399539 0.79 MAPT (0.51) MAPTMEN1KMT2AP4HBNFE2L2
SCHEMBL23794687 0.78 MAPT (0.64) MAPTMEN1KMT2AALDH1A1HPGD
SCHEMBL14109864 0.76 GPR52 (0.50) MAPTMEN1KMT2AALDH1A1HPGD
SCHEMBL16399501 0.75 NFE2L2 (0.46) MAPTMEN1KMT2AP4HBNFE2L2
SCHEMBL16399498 0.75 NFE2L2 (0.46) MAPTMEN1KMT2AP4HBNFE2L2
SCHEMBL13110217 0.75 MAPT (0.43) MAPTMEN1KMT2ANFE2L2HTT
SCHEMBL3335558 0.74 CDC7 (0.44) MAPTMEN1KMT2AALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4570313-A2 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2025-06-18 — — EP disclosed
EP-4219477-A1 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2023-08-02 — — EP disclosed
US-10626095-B2 Cyanotriazole compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-04-21 — — US disclosed
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-08-11 — — US disclosed
EP-3022199-A1 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2016-05-25 — — EP disclosed
WO-2015008872-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2015-01-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10626095-B2 Cyanotriazole compounds CS, PC, ACAT1 MAPT 2196/4885MEN1 3151/4885KMT2A 865/4885
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS CS, PC, ACAT1 MAPT 2196/4885MEN1 3151/4885KMT2A 865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback